The Pharmacy Times® Hematology Resource Center is a comprehensive resource for clinical news and expert insights on the treatment of blood disorders, include blood and bone marrow cancers, anemia, hemophilia, blood-clotting disorders, and leukemia.
May 16th 2024
The indication is for adult patients who have received at least 2 prior lines of systemic therapy and is based on the response rate and duration of response shown in a phase 2 trial.
Continuing the Conversation in Myelofibrosis: The Role of Managed Care in Supporting Treatment Goals Through Appropriate Use of Emerging Therapies
1.0 Credits / Hematology, Oncology
View More
Caring for Patients With Chronic Graft-versus-Host Disease: The Important Role of Pharmacists on the Cancer Care Team
1.5 Credits / Hematology, Oncology
View More
New Frontiers in the Treatment of Lower-Risk Myelodysplastic Syndromes and the Role of Oncology Pharmacists
1.5 Credit / Hematology, Oncology
View More
Advancing Myelofibrosis Treatment and Management With JAK Inhibitors and Specialty Pharmacist-led Strategies
1.5 Credits / Hematology
View More
Clinical Updates in AML Induction and Maintenance Regimens and the Role of the Specialty Pharmacist
1.5 Credit(s) / Hematology, Oncology
View More
Background and Key Concepts in Biosimilars: Improving Awareness and Addressing Common Concerns
1.0 Credit / Law
View More
Supporting Safe, Effective, and Equitable Access to B-Cell Maturation Antigen (BCMA)-Directed Treatments in Multiple Myeloma: Strategies for Specialty and Managed Care Pharmac...
1.5 Credit / Hematology, Oncology
View More
Exploring the Advancements in BTK Inhibitor Therapy for Mantle Cell Lymphoma and the Growing Impact of Oncology Pharmacists
1.0 Credit / Hematology, Oncology
View More
Clinical Conversations With the Cancer Care Team: Striving for Equitable Access to Oral Anticancer Medications
1.5 Credits / Law, Oncology
View More
Advances in the Treatment of Myelofibrosis: Updates and Considerations for Managed Care Professionals
1.0 Credit / Hematology, Oncology
View More
Assessing Emerging Therapies and Multidisciplinary Practices in Managing Myelofibrosis
1.5 Credits / Hematology, Oncology
View More
Chronic Myeloid Leukemia: Navigating Drug Resistance and Optimizing Care
1.0 Credit / Hematologic Cancer, Hematology, Oncology
View More
Optimizing Use of Small Molecule Inhibitors in Chronic Lymphocytic Leukemia: Strategies for Safe and Effective Use
1.0 Credits / Hematology, Oncology
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
Management of DOAC-Associated Bleeding With Reversal Agents: A Comprehensive Approach for Health-System Pharmacists
1.0 Credit / Hematology
View More
Keeping Pace With New Developments in Multiple Myeloma: Updates and Strategies to Optimize Bispecific Antibodies and CAR T-Cell Therapy
1.5 Credits / Oncology, Hematology, Hematologic Cancer
View More
Addressing the Gaps and Clinical Challenges in Chronic Lymphocytic Leukemia: Updates and Strategies for Managed Care
1.5 Credits / Hematology, Hematologic Cancer, Oncology
View More
Simulation Demonstrates Potential Effectiveness of Model-Informed Precision Dosing for Heparin
August 14th 2023The growing awareness in health care of the challenges associated with proper dosing of anticoagulants such as heparin has inspired the emerging field of anticoagulation stewardship.
Read More
Novel Combination Targeting BCR::ABL1 in Ph+ ALL With TKIs, STAMP-Inhibitor Is Very Well Tolerated
Pharmacists will play a significant role in TKI adherence rates among patients.
Read More
Case Study: New Treatment Options for Patients With Chronic Lymphocytic Leukemia
August 2nd 2023With a better understanding of the underlying pathophysiology of chronic lymphocytic leukemia and the introduction of novel targeted agents, such as Bruton kinase Inhibitors, the prognosis of high-risk patients has changed dramatically.
Read More
Axatilimab Produces Significant Response in Patients with Fatal Post-Transplant Complication
July 25th 2023Co-developers Incyte and Syndax will submit a biologics license application to the FDA at the end of 2023 based on the results of a phase 2 trial among adult and pediatric patients with chronic graft-versus-host disease.
Read More
As Chemotherapy Drug Shortage Continues, Unimaginable Decisions and Lacking Accountability Reign
July 24th 2023Treatment providers have been forced to adapt and make potentially life-altering decisions for patients due to persistent chemotherapy drug shortages, all while solutions from the FDA and drug manufacturers remain scant.
Read More
Expert Panel Discusses Advocacy, Education for Patients With Myeloproliferative Neoplasms
July 14th 2023Despite a slew of barriers with patient management, pharmacists have the training and resources to advocate for better patient care and help patients with hematologic myeloproliferative neoplasms advocate for themselves.
Read More
Luspatercept-aamt Shows Efficacy Treating Anemia Due to Myelodysplastic Syndromes
June 19th 2023Trial results demonstrated that 58.5% of individuals receiving luspatercept-aamt (Reblozyl; Bristol Myers Squibb) achieved the primary endpoint of red blood cell transfusion independence of at least 12 weeks.
Read More
USC ALL Induction Regimen Combined With Newer TKIs Is Safe, Effective for Patients With Ph+ Disease
Achieving MRD flow cytometry negativity is crucial in monitoring and predicting survival outcomes.
Read More
Cilta-Cel Shows Long-Term Efficacy in Patients With Relapsed/Refractory Multiple Myeloma
June 13th 2023A single infusion of ciltacabtagene autoleucel produced a lower risk of death and disease progression, as well as deep and durable responses, in heavily pretreated patients with relapsed/refractory multiple myeloma.
Read More